RxDoctor Payments Data

Juliya Fisher, MD

MOHS-Micrographic Surgery · Brooklyn, NYNPI 1609293760

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 27.0% of the total. Reporting peaked in 2020 at $852 and has fallen 71.2% since, to $246 in 2025.

$4,213in general payments, 2019–2025

Across 154 payments — averaging $27.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$499
  • Merz North America, Inc.$438
  • Amgen$416
  • Galderma Laboratories, L.p.$321
  • Sun Pharmaceutical Industries Inc.$207
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,13398%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,213 in reported general payments places this provider in the 70th percentile of 75 mohs-micrographic surgery providers in New York.

See all mohs-micrographic surgery providers in New York

Medicare billing

Part B allowed, 2024
$177,075
Medicare patients
191
Services billed
1,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate13$686
Metronidazole11$566
Ketoconazole11$113
Triamcinolone Acetonide14$110

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →